Needle-Free Growth Hormone Delivery Compared to Standard Injection
Author Information
Author(s): Chris Brearley, Anthony Priestley, James Leighton-Scott, Michel Christen
Primary Institution: Serono International SA
Hypothesis
The study aims to assess the bioequivalence of recombinant human growth hormone administered by a new needle-free device compared to a standard needle and syringe.
Conclusion
The cool.click™ 2 device delivers r-hGH exposure that is bioequivalent to the conventional needle and syringe method.
Supporting Evidence
- The pharmacokinetic parameters showed no significant difference between the two administration methods.
- The new device was well tolerated by participants.
- The study demonstrated that the new device could improve patient adherence to treatment.
Takeaway
This study shows that a new needle-free device for delivering growth hormone works just as well as using a regular needle, making it easier and less scary for patients.
Methodology
A randomized, two-period, two-sequence crossover study was conducted with 38 healthy volunteers to compare the pharmacokinetics of r-hGH administered by cool.click™ 2 and a standard syringe.
Limitations
The study was limited to healthy male volunteers aged 21-50, which may not represent the broader population of growth hormone deficiency patients.
Participant Demographics
Healthy male volunteers aged 21-50 with a BMI of 22-30 kg/m2.
Statistical Information
P-Value
0.002
Confidence Interval
90% CI for Cmax: 103.7–118.3; AUC0-inf: 97.1–110.0
Statistical Significance
p = 0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website